A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience

Abstract Background Vigabatrin (VGB) is one of two FDA-approved medications for treatment of infantile spasms. Despite demonstrated efficacy, its use has been curtailed by reports indicating a substantial risk of VGB-associated visual field loss (VAVFL). As these reports have conflicted with our cli...

Ausführliche Beschreibung